Ozone Therapy

Ozone therapy has extensive European clinical use and a growing evidence base, though quality varies by application. A 2025 randomized controlled trial (Frontiers in Medicine, n=62) found ozone major autohemotherapy added to standard care improved neurological recovery (NIHSS, Barthel Index, MoCA scores) after acute ischemic stroke with no signal of organ toxicity -- an early, single-center finding that needs replication before broader use. A 2025 meta-analysis of 13 RCTs (Evidence-Based Dentistry) found ozone as an adjunct to periodontal scaling and root planing modestly reduced pocket depth and gingival inflammation versus scaling alone, with no significant benefit for plaque control or attachment level. Antimicrobial and immune-modulatory effects remain the best-supported mechanisms. Ozone therapy is not FDA-approved; the FDA issued a 2019 consumer warning citing insufficient evidence of safety and effectiveness, so it should be pursued only through experienced practitioners following established safety protocols (G6PD deficiency screening, proper gas-phase administration to avoid embolism).

Evidence Scale